Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Menicon CoMNNLF 74 3-Year EBITDA Growth Rate is 5.00% as of Mar. 2026, which is 25% below its 10-year median of 6.70. GuruFocus rates MNNLF with a GF Score™ of 74/100 and a GF Value™ of $7.39 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Menicon Co ranks worse than 55.52% on this metric.
During the past 12 months, Menicon Co's average EBITDA Per Share Growth Rate was 20.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 5.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 5.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 8.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Menicon Co was 15.40% per year. The lowest was 0.10% per year. And the median was 6.70% per year.
Menicon Co (OTCPK:MNNLF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Menicon Co 3-Year EBITDA Growth Rate Related Terms
MNNLF vs ISRG, BDX, RMD: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Menicon Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Menicon Co 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Menicon Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Menicon Co's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 5.00% mean?
Menicon Co (MNNLF) has a 3-Year EBITDA Growth Rate of 5.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Menicon Co and its competitors. This is 25% below median its historical median of 6.70. Over the past decade, Menicon Co's 3-Year EBITDA Growth Rate has ranged from 0.10 to 15.40. According to the industry distribution chart, Menicon Co ranks #382 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 55.5%.
Is Menicon Co's 3-Year EBITDA Growth Rate too high?
Menicon Co's current 3-Year EBITDA Growth Rate of 5.00% is 25% below median its 10-year median of 6.70. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 15.40. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Menicon Co's value of 5.00% is 38.3% below this industry median. Based on the distribution chart, Menicon Co ranks #382 out of 688 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Menicon Co has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Menicon Co's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Menicon Co ranks #382 out of 688 companies for 3-Year EBITDA Growth Rate. This places Menicon Co in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. Menicon Co's value of 5.00% is 38.3% below this benchmark. Historically, Menicon Co's own 3-Year EBITDA Growth Rate has ranged from 0.10 to 15.40 over the past decade. While the company's 10-year median is 6.70 vs. the industry median of 8.10, Menicon Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Menicon Co's current 3-Year EBITDA Growth Rate of 5.00% is 38.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Menicon Co and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Menicon Co's current 3-Year EBITDA Growth Rate is 5.00%, which is 25% below median its own 10-year median of 6.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Menicon Co stock overvalued right now?
Based on GuruFocus' analysis, Menicon Co (MNNLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.39, compared to a current price of $9.97 — trading 34.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 5.00%, which is 25% below median its 10-year median of 6.70 and 38.3% below the Medical Devices & Instruments industry median of 8.10. Menicon Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Menicon Co (MNNLF), the current 3-Year EBITDA Growth Rate is 5.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Menicon Co (MNNLF) Overvalued in 2026?
Based on GuruFocus' analysis, Menicon Co stock appears to be overvalued.
The current stock price of $9.97 is trading 34.8% above its estimated GF Value™ of $7.39.
GuruFocus considers Menicon Co to be Significantly Overvalued.
Key valuation signals for MNNLF:
3-Year EBITDA Growth Rate: 5.00% (25% below median its 10-year median of 6.70)
GF Value™: $7.39 vs. price of $9.97 (34.8% above fair value)
Industry Position: 38.3% below the Medical Devices & Instruments median (#382 of 688)
No single metric tells the full story. See the MNNLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Menicon Co Ltd is a contact lens manufacturing company. It is involved in manufacturing, sales, export, and import of contact lenses and other medical goods, manufacturing and sales of medical instruments, sales of medical supplies and research and development of intraocular lenses. The firm's products include soft lenses, gas permeable lenses and lens care products.
74GF Score
Get the complete analysis for MNNLF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNNLF has been successfully added to your 
